CUL7 is a novel antiapoptotic oncogene

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9616-9622

  Kim, Sam S ^a,b   Shago, Mary ^a,d   Kaustov, Lilia ^a   Boutros, Paul C ^a,b   Clendening, James W ^a,b   Sheng, Yi ^a   Trentin, Grace A ^a   Barsyte Lovejoy, Dalia ^a   Mao, Daniel Y L ^a   Kay, Robert ^c   Jurisica, Igor ^a,b   Arrowsmith, Cheryl H ^a,b   Penn, Linda Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; MYC PROTEIN; PROTEIN CUL7; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CULLIN PROTEINS; HUMANS; ONCOGENES; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35449007606     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0644     Document Type: Article

References (30)

1. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002; 84:81-154.
2. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69: 119-28.
3. Lindstrom MS, Klangby U, Wiman KG. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001; 20:2171-7.
4. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
5. Oster SK, Marhin WW, Asker C, et al. Myc is an essential negative regulator of platelet-derived growth factor β receptor expression. Mol Cell Biol 2000;20:6768-78.
6. Whitehead I, Kirk H, Kay R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol Cell Biol 1995;15:704-10.
7. Conzen SD, Gottlob K, Kandel ES, et al. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol 2000;20:6008-18.
8. Dias DC, Dolios G, Wang R, Pan ZQ. CUL7: A DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc Natl Acad Sci U S A 2002;99:16601-6.
9. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
10. Barsyte-Lovejoy D, Lau SK, Boutros PC, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 2006;66:5330-7.
11. Ruppert JM, Stillman B. Analysis of a protein-binding domain of p53. Mol Cell Biol 1993;13:3811-20.
12. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
13. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
14. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-54.
15. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
16. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65:1678-86.
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
18. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
19. Arai T, Kasper JS, Skaar JR, Ali SH, Takahashi C, DeCaprio JA. Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis. Proc Natl Acad Sci U S A 2003;100:9855-60.
20. Huber C, Dias-Santagata D, Glaser A, et al. Identification of mutations in CUL7 in 3-Msyndrome. Nat Genet 2005;37:1119-24.
21. Andrews P, He YJ, Xiong Y. Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 2006;25:4534-48.
22. Tsai SC, Pasumarthi KB, Pajak L, et al. Simian virus 40 large T antigen binds a novel Bcl-2 homology domain 3-containing proapoptosis protein in the cytoplasm. J Biol Chem 2000;275:3239-46.
23. Ali SH, Kasper JS, Arai T, DeCaprio JA. Cul7/p185/ p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004;78:2749-57.
24. Dowell JD, Tsai SC, Dias-Santagata DC, et al. Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding. Biochim Biophys Acta 2007;1773:358-66.
25. Stone J, de Lange T, Ramsay G, et al. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 1987;7:1697-709.
26. Kasper JS, Arai T, DeCaprio JA. A novel p53-binding domain in CUL7. Biochem Biophys Res Commun 2006; 348:132-8.
27. Kaustov L, Lukin J, Lemak A, et al. The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53. J Biol Chem 2007;282:11300-7.
28. Jung P, Verdoodt B, Bailey A, Yates JR III, Menssen A, Hermeking H. Induction of Cullin 7 by DNA damage attenuates p53 function. Proc Natl Acad Sci U S A 2007; 104:11388-93.
29. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.
30. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.